A Hershko
Overview
Explore the profile of A Hershko including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
92
Citations
9023
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Amital H, Heilweil-Harel M, Ulmansky R, Harlev M, Toubi E, Hershko A, et al.
Rheumatology (Oxford)
. 2007 Aug;
46(9):1433-7.
PMID: 17686790
Objective: We have previously shown that murine pathogenic lupus autoantibodies bind to VRT101, a 21-mer peptide located at the globular part of the laminin-alpha chain. In this study, we evaluated...
2.
Hershko A
Cell Death Differ
. 2005 Aug;
12(9):1191-7.
PMID: 16094395
Owing to the intensive research activity on protein synthesis, little attention was paid in the 1950s and 1960s to protein degradation. However, work by my group and others between 1970...
3.
Abuksis G, Orenstein S, Hershko A, Michowiz R, Livne M, Loia N, et al.
Transplant Proc
. 2004 Jul;
36(5):1249-52.
PMID: 15251304
Background: Cornea transplantation provides a second chance for people with poor visual function. Unfortunately, there is a major shortage of donor cornea tissue. The purpose of this study was to...
4.
Azaz-Livshits T, Hershko A, Ben-Chetrit E
Pharmacopsychiatry
. 2002 Jul;
35(3):112-5.
PMID: 12107856
We recently encountered 3 patients who had developed reversible paroxetine-associated hepatotoxicity. Two of the patients were over 80 years old and their hepatitis was accompanied by hyponatremia. In the third...
5.
Hershko D, Bornstein G, Ben-Izhak O, Carrano A, Pagano M, Krausz M, et al.
Cancer
. 2001 May;
91(9):1745-51.
PMID: 11335900
Background: Previous studies have shown that low levels of p27(Kip1), an inhibitor of G1 cyclin-dependent kinases, are associated with high aggressiveness and poor prognosis in a variety of cancers. Decreased...
6.
Ganoth D, Bornstein G, Ko T, LARSEN B, Tyers M, Pagano M, et al.
Nat Cell Biol
. 2001 Mar;
3(3):321-4.
PMID: 11231585
The cyclin-dependent kinase (CDK) inhibitor p27 is degraded in late G1 phase by the ubiquitin pathway, allowing CDK activity to drive cells into S phase. Ubiquitinylation of p27 requires its...
7.
Hershko A, Ciechanover A, Varshavsky A
Nat Med
. 2000 Oct;
6(10):1073-81.
PMID: 11017125
No abstract available.
8.
Yudkovsky Y, Shteinberg M, Listovsky T, Brandeis M, Hershko A
Biochem Biophys Res Commun
. 2000 May;
271(2):299-304.
PMID: 10799291
The cyclosome/anaphase promoting complex (APC) is a multisubunit ubiquitin ligase that targets mitotic regulators for degradation in exit from mitosis. It is activated at the end of mitosis by phosphorylation...
9.
Hershko A
Philos Trans R Soc Lond B Biol Sci
. 1999 Dec;
354(1389):1571-5; discussion 1575-6.
PMID: 10582242
The degradation of the cyclin B subunit of protein kinase Cdk1/cyclin B is required for inactivation of the kinase and exit from mitosis. Cyclin B is degraded by the ubiquitin...
10.
Carrano A, Eytan E, Hershko A, Pagano M
Nat Cell Biol
. 1999 Nov;
1(4):193-9.
PMID: 10559916
Degradation of the mammalian cyclin-dependent kinase (CDK) inhibitor p27 is required for the cellular transition from quiescence to the proliferative state. The ubiquitination and subsequent degradation of p27 depend on...